As of Thursday, February 26, Ligand Pharmaceuticals Incorporated’s LGND share price has dipped by 5.99%, which has investors ...
Fintel on MSN
Ligand Pharmaceuticals Incorporated - Equity Right (LGNDZ) price target decreased by 76.23% to 0.00
The average one-year price target for Ligand Pharmaceuticals Incorporated - Equity Right (OTCPK:LGNDZ) has been revised to $0.00 / share. This is a decrease of 76.23% from the prior estimate of $0.01 ...
Q4 2025 earnings call recap: royalty revenue up 48%, 2026 guidance reaffirmed, and 23% royalty CAGR to 2030—read key catalysts now.
4 analysts have expressed a variety of opinions on Ligand Pharmaceuticals (NASDAQ:LGND) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides a ...
Wall Street remains bullish on the stock. All eight analysts covering Ligand rate it a buy, with a consensus price target of $244.33 implying 29% upside from the current $189 share price. The company ...
Royalty Aggregators like Royalty Pharma, Ligand, and XOMA are gaining popularity in the biotech industry. These companies buy up royalty rights to pharmaceutical products, providing upfront cash to ...
Delaware-based Ashford Capital Management sold 58,097 shares of Ligand Pharmaceuticals for an estimated $8.9 million in the third quarter. The transaction value equaled about 1% of 13F reportable ...
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Verona Pharma plc has received approval from the U.S. Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results